Targeted Chronic Myeloid Leukemia Drugs Show Divergent Cardiovascular Risk Profiles, JACC Cardio-Oncology State-of-the-...
A recent state-of-the-art review highlights that Cardiovascular disease (CVD) and CV risk factors are frequent in patients with Chronic Myeloid Leukemia (CML). Therefore, it is crucial to evaluate the CV safety profile of various BCR::ABL1 (Breakpoint …